FDA granted priority review for a gene therapy, while the company Rocket was listed on the Nasdaq stock exchange.
1 report, 1 independent
Updated Jun 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted priority review for a gene therapy, while the company Rocket was listed on the Nasdaq stock exchange.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- The FDA reversed its decision regarding a gene therapy application from uniQure N.V.
- Precigen's therapy was approved by the FDA and listed on Nasdaq, while Trump-era tariffs are reported to benefit certain AI stocks.
- Benchmark and Jefferies reaffirmed buy ratings while the FDA cited toxicity findings for Bright Minds Biosciences Inc.
- FDA oversees drug trials in the US and Israel for Clearmind Medicine Inc., which is listed on Nasdaq.